Gossamer Bio, Inc.

Gossamer Bio, Inc.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension and related diseases.

3115 Merryfield Row, Suite 120 San Diego CA 92121

Workers Affected

65

Notice Date

April 8, 2026

Effective date

May 15, 2026

Expiration Date

Unavailable

Permanent or Temporary

Permanent

Unavailable

Closure or layoff

Layoff

Union

Unavailable

Industry

Unavailable

54 Professional, Scientific, and Technical Services

Contact Name

Unavailable

Contact Email

Unavailable

Contact Phone

Unavailable

Source

Unavailable

More WARN Notices from 

Gossamer Bio, Inc.

View All Notices
Sorry, no more notices available.
We have immediate access to ~300 days of notices. if you are looking for notices further back, please contact us below.
support@warnwise.org